Advertisement
Evolocumab halves cardiovascular events in exploratory analysis
Unprecedented LDL-C reductions raise hopes for long-term outcome trials
A leading cardiologist weighs in on which presentations are likely to matter most to patient care
New agents show powerful cholesterol-lowering ability—and appear safe so far
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
Advertisement